Corebridge Financial Inc. Decreases Holdings in Hologic, Inc. (NASDAQ:HOLX)

Corebridge Financial Inc. decreased its stake in Hologic, Inc. (NASDAQ:HOLX) by 4.6% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 54,973 shares of the medical equipment provider’s stock after selling 2,671 shares during the period. Corebridge Financial Inc.’s holdings in Hologic were worth $3,963,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in HOLX. State Street Corp raised its holdings in shares of Hologic by 0.8% in the 3rd quarter. State Street Corp now owns 10,409,327 shares of the medical equipment provider’s stock worth $847,944,000 after purchasing an additional 81,057 shares during the period. Victory Capital Management Inc. raised its stake in shares of Hologic by 0.5% in the fourth quarter. Victory Capital Management Inc. now owns 4,917,551 shares of the medical equipment provider’s stock valued at $354,506,000 after buying an additional 24,358 shares during the period. Boston Partners lifted its position in shares of Hologic by 81.0% during the 4th quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider’s stock valued at $257,959,000 after buying an additional 1,602,463 shares during the last quarter. Nordea Investment Management AB grew its stake in shares of Hologic by 32.7% during the 4th quarter. Nordea Investment Management AB now owns 2,213,607 shares of the medical equipment provider’s stock worth $159,911,000 after acquiring an additional 544,889 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Hologic by 0.8% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,971,617 shares of the medical equipment provider’s stock worth $160,608,000 after acquiring an additional 16,057 shares during the last quarter. 94.73% of the stock is currently owned by hedge funds and other institutional investors.

Hologic Trading Down 1.6 %

NASDAQ HOLX opened at $61.32 on Monday. The company has a quick ratio of 2.78, a current ratio of 3.49 and a debt-to-equity ratio of 0.52. The stock’s 50-day simple moving average is $65.24 and its two-hundred day simple moving average is $73.24. Hologic, Inc. has a twelve month low of $60.34 and a twelve month high of $84.67. The company has a market capitalization of $13.76 billion, a price-to-earnings ratio of 19.34, a PEG ratio of 2.14 and a beta of 0.97.

Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share for the quarter, topping analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. Research analysts forecast that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Wall Street Analyst Weigh In

HOLX has been the subject of a number of research reports. Evercore ISI cut their target price on shares of Hologic from $76.00 to $73.00 and set an “in-line” rating for the company in a research report on Thursday, February 6th. Leerink Partnrs downgraded shares of Hologic from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 6th. Wolfe Research initiated coverage on shares of Hologic in a report on Friday, December 13th. They set a “peer perform” rating on the stock. Citigroup cut their price target on Hologic from $80.00 to $70.00 and set a “neutral” rating for the company in a report on Tuesday, March 4th. Finally, Morgan Stanley decreased their price objective on Hologic from $84.00 to $82.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Eleven equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Hologic currently has a consensus rating of “Hold” and a consensus price target of $84.62.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.